STRO
NASDAQSutro Biopharma Inc.
Price$25.95+0.17 (+0.66%)
01:45 PM07:45 PM
News · 26 weeks65-15%
2025-12-142026-06-07
Mix3490d
- SEC Filings11(32%)
- Insider9(26%)
- Other8(24%)
- Analyst6(18%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Wigginton Jon Marc4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Petree Daniel H4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Panek James P4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Lobacki Joseph M4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Jagpal Sukhi4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Hunter Heidi4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Dybbs Michael4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- INSIDERSEC Form 4 filed by Director Matsui Connie4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- SECSEC Form 8-K filed by Sutro Biopharma Inc.8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- INSIDERCFO Chow Gregory K. converted options into 2,500 shares, increasing direct ownership by 112% to 4,725 units (SEC Form 4) (withholding obligation)4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
- ANALYSTBarclays initiated coverage on Sutro Biopharma with a new price targetBarclays initiated coverage of Sutro Biopharma with a rating of Overweight and set a new price target of $56.00
- SECSEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.SCHEDULE 13G - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- ANALYSTSutro Biopharma upgraded by Wedbush with a new price targetWedbush upgraded Sutro Biopharma from Neutral to Outperform and set a new price target of $60.00
- SECSEC Form 10-Q filed by Sutro Biopharma Inc.10-Q - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- SECSutro Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- PRSutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRA
- ANALYSTMizuho initiated coverage on Sutro Biopharma with a new price targetMizuho initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $50.00
- SECSEC Form DEFA14A filed by Sutro Biopharma Inc.DEFA14A - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- SECSEC Form DEF 14A filed by Sutro Biopharma Inc.DEF 14A - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- SECSEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.SCHEDULE 13G - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
- PRSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical
- ANALYSTLeerink Partners initiated coverage on Sutro Biopharma with a new price targetLeerink Partners initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $38.00
STRO FAQ
7 questionsWhat does Sutro Biopharma Inc. do?
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and...Where does STRO stock trade?
Sutro Biopharma Inc. (STRO) is listed on NASDAQ.What sector and industry is STRO in?
Sutro Biopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Sutro Biopharma Inc. go public?
Sutro Biopharma Inc. (STRO) completed its IPO in 2018.What are analysts saying about STRO?
Sutro Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-05-28.What companies are similar to STRO?
Notable peers in the same industry include CUE (Cue Biopharma Inc.), GTBP (GT Biopharma Inc.), MTNB (Matinas Biopharma Holdings Inc.). Compare STRO side-by-side with any of them on Quantisnow.How can I track STRO on Quantisnow?
Quantisnow aggregates Sutro Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STRO to receive live email and push alerts on every new disclosure.